Navegación
Cerrar
Servicios
Corporate Finance
Desde 1990, Mirabaud ofrece una amplia gama de servicios de asesoramiento y ejecución a un creciente número de empresas cotizadas y privadas. Su oferta comprende análisis financiero, servicios de ejecución, conocimiento especializado en mercados de capitales, financiación e intermediación institucional.
Scailyte
Case Study
Scailyte
Mirabaud acted as the Company's exclusive advisor in the structuring, execution and completion of the fundraising process of CHF 6M for the Series A funding of Scailyte.
About Scailyte
- Scailyte, a Swiss company founded in 2017 as an ETH Zürich spin-off and based in Basel at the Novartis Campus (Switzerland) and in Cambridge-MA (USA), aims at advancing precision medicine with single-cell technologies, artificial intelligence, and multi-omics analysis.
- The company has developed a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell data and is composed of the two business units:
- ScaiVision –providing services and establishing co-development projects – and
- ScaiDx –developing proprietary biomarkers.
- Scailyte has developed biomarker signatures in diverse therapeutic areas with high level of accuracy and has the potential to span from discovery to translation into clinics and diagnostics.
Transaction overview
- The scope of the project was to support the Scailyte’s fundraising process and help it secure the completion of the CHF 6M Series A round of financing with new resources to allow the Company to accelerate the achievement of its development and commercial milestones.
- The Series A funding was coordinated by Mirabaud by collaborating with a Swiss family office, previous investors including Swiss-based institutional investors and an established Mirabaud bank vehicle.
- Scailyte’s priorities will be focused on:
- progressing their biomarkers, with the United States as the primary target market;
- building strategic partnerships in single-cell omics, cell & gene therapy, and translational oncology to increase the success rate of clinical trials for novel anti-cancer therapies;
- expanding the discovery capabilities of its best-in-class single-cell analytics platform.
Mirabaud contribution and added value
- Mirabaud acted as the Company's exclusive advisor in the structuring, execution and completion of the fundraising process for the Series A funding of Scailyte.
- Mirabaud managed:
- structuring the T&Cs of the financing,
- preparation of the project information and coordination of the Due Diligence,
- elaboration of the Business Plan,
- estimation of the future value creation pathways;
- review of the legal documentation for the closing of the transaction.
- Mirabaud acted as the hub for the transaction by merging a differentiated and international community of investors in a very concrete and time-efficient manner towards a mutual objective.
Key data
Client | Scailyte AG |
Industry vertical | Digital Healthcare |
Typology | Capital growth |
Target | CHF 6'000’000 |
Mirabaud’s role | Exclusive Advisor |
Case Study